Ambrx Biopharma EBITDA 2020-2021 | AMAM
Ambrx Biopharma ebitda from 2020 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| Ambrx Biopharma Annual EBITDA (Millions of US $) |
|
|---|---|
| 2021 | $-62 |
| 2020 | $-11 |
| 2019 | $-20 |
| Ambrx Biopharma Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2021-12-31 | $7 |
| 2020-12-31 | |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.110B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $165.407B | 10.06 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.121B | 30.63 |
| QIAGEN (QGEN) | Netherlands | $10.180B | 16.07 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.170B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.223B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.792B | 45.42 |
| Emergent Biosolutions (EBS) | United States | $1.625B | 6.95 |
| Myovant Sciences (MYOV) | United Kingdom | $1.313B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.365B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.122B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.099B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
